Case Reports Open access

Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors

Authors

Published
10 February 2025
Section
Case Reports

Abstract

We present a case of interstitial lung disease arising in the course of antisynthetase syndrome (ASSD) in a patient with axial spondyloarthritis (ax-SpA) undergoing tumor necrosis factor-α (TNF-α) inhibitor therapy. Only two cases of ASSD in ax-SpA patients have been described in the literature, although with a different autoantibody profile. Only in one case, ASSD manifested with lung involvement, without the possible implication of TNF-α inhibitors in the pathogenesis, as it occurred concurrently with spondyloarthritis. Our case is the first to emphasize the coexistence of ASSD with anti-glycyl tRNA synthetase antibodies and ax-SpA, reminding us of the possible, although rare, adverse effects on the lungs with TNF-α inhibitors.

References

  1. Sawal N, Mukhopadhyay S, Rayancha S, Moore A, Garcha P, Kumar A, et al. A narrative review of interstitial lung disease in antisynthetase syndrome: a clinical approach. J Thorac Dis 2021; 13: 5556-71. DOI: https://doi.org/10.21037/jtd-20-3328
  2. Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 2022; 61: 1760-8. DOI: https://doi.org/10.1093/rheumatology/keac115
  3. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83. DOI: https://doi.org/10.1136/ard.2009.108233
  4. Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Corte TJ, Doyle TJ, et al. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol 2022; 40: 309-19. DOI: https://doi.org/10.55563/clinexprheumatol/8xj0b9
  5. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13: 175-81. DOI: https://doi.org/10.1007/s11926-011-0176-8
  6. Chawla A, Kumar T, Mukherjee P. Antisynthetase syndrome: Initial and follow-up imaging features. Lung India 2018; 35: 523-5. DOI: https://doi.org/10.4103/lungindia.lungindia_4_18
  7. Meyer O, Charlanne H, Cherin P, Allanore Y, Coquerelle P, Grardel B, et al. Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann Rheum Dis 2009; 68: 152-3. DOI: https://doi.org/10.1136/ard.2007.078907
  8. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73: 227-32. DOI: https://doi.org/10.1136/annrheumdis-2012-201800
  9. Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med 2019; 8: 2013. DOI: https://doi.org/10.3390/jcm8112013
  10. Bozzalla-Cassione E, Zanframundo G, Biglia A, Bellis E, Bozzini S, Codullo V, et al. Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol 2022; 40: 27-31. DOI: https://doi.org/10.55563/clinexprheumatol/bjb2gf
  11. Ge Y, He L. Coexistence of axial spondyloarthritis and idiopathic inflammatory myopathy. Case Rep Rheumatol 2020; 2020:8840642. DOI: https://doi.org/10.1155/2020/8840642
  12. Nouijai A, Ghazi M, Mounach A, Achemlal L, Bezza A, El Maghraoui A. Antisynthetase syndrome in a patient with ankylosing spondylitis. Joint Bone Spine 2007; 74: 511-2. DOI: https://doi.org/10.1016/j.jbspin.2007.01.028
  13. Chen HH, Chao WC, Chen YH, Hsieh TY, Lai KL, Chen YM, et al. Risk of immunemediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study. Arthritis Res Ther 2019; 21: 196. DOI: https://doi.org/10.1186/s13075-019-1980-1
  14. Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal 2014; 2014: 179180. DOI: https://doi.org/10.1155/2014/179180
  15. Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med 2015; 30: 104-9. DOI: https://doi.org/10.3904/kjim.2015.30.1.104

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.